WHO Global resources to respond to the COVID-19 pandemic
Promoting global equitable access to health technologies

28 February 2022 | Access to Medicines & Health Products | DUENASE@WHO.INT
WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA-PHI)

8 Elements GSPA-PHI remain valid

1. Prioritizing research and development needs
2. Promoting research and development
3. Building and improving innovative capacity
4. Transfer of technology
5. Application and management of intellectual property
6. Improving delivery and access
7. Promoting sustainable financing mechanisms
8. Establishing and monitoring reporting systems

Global_Strategy_Plan_Action.pdf (who.int)
Technology transfer and management of IP Elements 4 & 5

➢ Facilitate widespread access to, and promote further development of, including, if necessary, compiling, maintaining and updating, user-friendly global databases that contain public information on the administrative status of health-related patents, including supporting the existing efforts for determining the patent status of health products, in order to strengthen national capacities for analysis of the information contained in those databases.

➢ Facilitate local and regional networks for collaboration on research and development and transfer of technology;

➢ Promote and monitor coverage and use of databases on patent status and licensing information for health technologies including for COVID-19 vaccines, therapeutics, diagnostics and other health technologies.
WHO C-TAP
Global Database

• WHO launched the Solidarity Call to Action and the COVID-19 Technology Access Pool (C-TAP) to promote sharing of data, know-how and IP of COVID-19 diagnostics, treatment and vaccines, to facilitate technology transfer and scale up production worldwide.

https://www.who.int/initiatives/covid-19-technology-access-pool/solidarity-call-to-action

• The COVID-19 Technology Access Pool is developing a Global database to include COVID-19 health technologies one-stop-shop publicly available information: patent status, licensing, regulatory status, clinical trials, manufacturers (originators & generics), WHO PQ, EUL, market exclusivities, etc. (Will be launched March 2022)

https://www.who.int/initiatives/covid-19-technology-access-pool/
## WHO C-TAP Global Database

### User interface

**Search by keywords**

**WHO Region**
- **ALL X**

**Country**
- **INDONESIA X**

**Product Type**
- **ALL X**

**Add/Remove Columns**
- Market Exclusivities
- National (EUL by Country)
- Tech Transfer Agreement
- NRA Approval

**Product**

### Data Table

<table>
<thead>
<tr>
<th>Country</th>
<th>WHO Region</th>
<th>Product Type</th>
<th>Product Name</th>
<th>Patent Number</th>
<th>Patent Status</th>
<th>Licensing status</th>
<th>WHO Reg...EUL</th>
<th>PQP...WLA</th>
<th>Man... (Org...</th>
<th>Man... (Gen...</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indonesia</td>
<td>South-East Asia Region</td>
<td>Therapeutic</td>
<td>AT-527</td>
<td>ID201202589</td>
<td>Rejected</td>
<td>Granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>South-East Asia Region</td>
<td>Therapeutic</td>
<td>Balotinib 2 mg</td>
<td>ID2012007725</td>
<td>Rejected</td>
<td>Granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>South-East Asia Region</td>
<td>Therapeutic</td>
<td>Caskirvacab +Indomabab (RECN-COVID) 150.6 mg/ml+mg/ml</td>
<td>ID201201693121</td>
<td>Granted</td>
<td>Granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>South-East Asia Region</td>
<td>Therapeutic</td>
<td>Darunavir/Colectrafat 800/150 mg</td>
<td>ID201202103307</td>
<td>Filed</td>
<td>Granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>South-East Asia Region</td>
<td>Therapeutic</td>
<td>Cov2 proS dTM-AS63 0.5 ml</td>
<td>ID201200791413</td>
<td>Filed</td>
<td>Granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>South-East Asia Region</td>
<td>Therapeutic</td>
<td>Dapagliflozin 10 mg</td>
<td>ID2012007900469</td>
<td>Expired</td>
<td>Granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>South-East Asia Region</td>
<td>Therapeutic</td>
<td>Sofosbuvir/Dacabavir 400+80 mg</td>
<td>ID2012008695202</td>
<td>Granted</td>
<td>Granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>South-East Asia Region</td>
<td>Therapeutic</td>
<td>Sofosbuvir/Dacabavir 400/80 mg</td>
<td>ID201200146555</td>
<td>Granted</td>
<td>Granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>South-East Asia Region</td>
<td>Therapeutic</td>
<td>Empagliflozin 10 mg</td>
<td>ID201200146555</td>
<td>Expired</td>
<td>Granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>South-East Asia Region</td>
<td>Therapeutic</td>
<td>Favipiravir 200 mg</td>
<td>ID2012001301476</td>
<td>Expired</td>
<td>Granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Additional**

- **Export to Excel**
- **Email this search**
WHO C-TAP Global Database
Links to other WHO databases
WHO works in collaboration with the Medicines Patent Pool (MPP) and since the beginning of the pandemic the MPP expanded its Medicines Patents and Licences Database (MedsPaL) to include key COVID-19 products.

https://www.medspal.org/

WHO requested MPP to make available patent status information on COVID-19 vaccines. Recently the MPP launched COVID-19 Vaccines Patent Landscape (VaxPaL).

https://www.vaxpal.org/
WHO additional resources


➢ **Therapeutics and COVID-19 (who.int)** WHO develops the most up-to-date clinical practice guidelines for the use of therapeutics for patients with COVID-19 based on ongoing assessment of new evidence generated by the international medical research community and first responders

➢ **WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)** WHO prequalification aims to ensure that key health products meet global standards of quality, safety and efficacy, in order to optimize use of health resources and improve health outcomes.

➢ **COVID-19 vaccine tracker and landscape (who.int)** Compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline.

➢ **COVID-19_PQ_Tracking_22Feb2022.pdf (who.int)** (Therapeutics)
Thank you